DK3914247T3 - Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom - Google Patents

Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom Download PDF

Info

Publication number
DK3914247T3
DK3914247T3 DK20708283.5T DK20708283T DK3914247T3 DK 3914247 T3 DK3914247 T3 DK 3914247T3 DK 20708283 T DK20708283 T DK 20708283T DK 3914247 T3 DK3914247 T3 DK 3914247T3
Authority
DK
Denmark
Prior art keywords
migalostat
patients
risk
reduce
cerebrovascular events
Prior art date
Application number
DK20708283.5T
Other languages
Danish (da)
English (en)
Inventor
Nina Skuban
Hjalmar Lagast
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69726736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3914247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3914247T3 publication Critical patent/DK3914247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK20708283.5T 2019-01-22 2020-01-22 Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom DK3914247T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22
PCT/US2020/014531 WO2020154354A1 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease

Publications (1)

Publication Number Publication Date
DK3914247T3 true DK3914247T3 (da) 2025-01-27

Family

ID=69726736

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20708283.5T DK3914247T3 (da) 2019-01-22 2020-01-22 Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom

Country Status (17)

Country Link
US (1) US20220087993A1 (https=)
EP (2) EP4523750A3 (https=)
JP (2) JP7680356B2 (https=)
AR (1) AR117861A1 (https=)
DK (1) DK3914247T3 (https=)
ES (1) ES3007212T3 (https=)
FI (1) FI3914247T3 (https=)
HR (1) HRP20250078T1 (https=)
HU (1) HUE069934T2 (https=)
LT (1) LT3914247T (https=)
PL (1) PL3914247T3 (https=)
PT (1) PT3914247T (https=)
RS (1) RS66410B1 (https=)
SI (1) SI3914247T1 (https=)
SM (1) SMT202500034T1 (https=)
TW (1) TW202042812A (https=)
WO (1) WO2020154354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
PT3914247T (pt) 2025-01-23
PL3914247T3 (pl) 2025-04-14
EP3914247B1 (en) 2024-11-13
ES3007212T3 (en) 2025-03-19
FI3914247T3 (fi) 2025-02-16
RS66410B1 (sr) 2025-02-28
LT3914247T (lt) 2025-01-27
SI3914247T1 (sl) 2025-03-31
HRP20250078T1 (hr) 2025-03-28
SMT202500034T1 (it) 2025-03-12
HUE069934T2 (hu) 2025-04-28
EP3914247A1 (en) 2021-12-01
WO2020154354A1 (en) 2020-07-30
JP2022518733A (ja) 2022-03-16
EP4523750A3 (en) 2025-06-11
JP2025128105A (ja) 2025-09-02
US20220087993A1 (en) 2022-03-24
TW202042812A (zh) 2020-12-01
AR117861A1 (es) 2021-09-01
JP7680356B2 (ja) 2025-05-20
EP4523750A2 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
DK3750536T3 (da) Fremgangsmåder til at reducere risikoen for kardiovaskulære hændelser hos et individ
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
DK3472317T3 (da) Sammensætninger og fremgangsmåder til reduktion af okulær vaskularisation
EP3777807C0 (en) MULTIFUNCTIONAL WHEELCHAIR
DK3603524T3 (da) Indretning til digital billeddannelse i hovedregionen af en patient
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
DK3439660T3 (da) Anvendelse af pimobendan til reduktion af hjertestørrelse og forsinkelse af udbruddet af kliniske symptomer hos patienter med asymptomatisk hjertesvigt på grund af mitralklapsygdom
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
EP3321504A4 (en) CORRECTION OF SYSTEMATIC ERRORS IN THE ORIENTATION OF WIND TURBINES
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK4176877T3 (da) Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
DK2945967T3 (da) Et opløseligt fibroblastvækstfaktorreceptor 3 (fgr3)-polypeptid til anvendelse ved forebyggelse eller behandling af skeletvæksthæmningssygdomme
DK3916392T3 (da) Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter
DK3250600T3 (da) Behandling af autoimmune lidelser med cd154-antistoffer
DK3592355T3 (da) KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose
DK3191120T3 (da) Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
DK3476395T3 (da) Injicerbar sammensætning omfattende fibroblaster til anvendelse i behandlingen af hjertesygdomme
EP2988731A4 (en) COMPOSITION TO REDUCE CRUSTING AND TO PROMOTE WOUND HEALING
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
DK3779447T3 (da) Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer
DK3914247T3 (da) Anvendelse af migalostat til reducering af risikoen for cerebrovaskulær hændelse hos patienter med fabrys sygdom